EE494 Cost-Effectiveness Analysis of Axicabtagene Ciloleucel as a Second-Line Treatment for Diffuse Large B-Cell Lymphoma in ChinaPei Wang, Ming Hu, Xiao Ke et al.|Value in Health|2025Cited by 0